IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

Multiple myeloma (MM) patients who receive killer cell Ig–like receptor (KIR) ligand–mismatched, T cell–depleted, allogeneic transplantation may have a reduced risk of relapse compared with patients who receive KIR ligand–matched grafts, suggesting the importance of this signaling axis in the natura...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Benson, Don M., Bakan, Courtney E., Zhang, Shuhong, Collins, Shauna M., Liang, Jing, Srivastava, Shivani, Hofmeister, Craig C., Efebera, Yvonne, Andre, Pascale, Romagne, Francois, Bléry, Mathieu, Bonnafous, Cécile, Zhang, Jianying, Clever, David, Caligiuri, Michael A., Farag, Sherif S.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2011
Teme:
Immunobiology
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3490103/
https://ncbi.nlm.nih.gov/pubmed/22031859
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-06-360255
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items